Intrapatient Intermetastatic Heterogeneity Determined by Triple-Tracer PET Imaging in mCRPC Patients and Correlation to Survival: The 3TMPO Cohort Study

Frédéric Pouliot; Fred Saad; Étienne Rousseau; Patrick O. Richard; Atefeh Zamanian; Stephan Probst; Éric Lévesque; Vincent Castonguay; Nicolas Marcoux; Michele Lodde; Daniel Juneau; Zineb Hamilou; Jean‐Baptiste Lattouf; François-Alexandre Buteau; Michel Pavic; Jean‐François Castilloux; Bertrand Neveu; Guillaume F. Bouvet; Catherine Allard; Amélie Têtu; Brigitte Guérin; Jean‐Mathieu Beauregard

doi:10.2967/jnumed.124.268020

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Intrapatient intermetastatic heterogeneity (IIH) has been demonstrated in metastatic castration-resistant prostate cancer (mCRPC) patients and is of the utmost importance for radiopharmaceutical therapy (RPT) eligibility. This study was designed to determine the prevalence of IIH and RPT eligibility in mCRPC patients through a triple-tracer PET imaging strategy.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Pouliot et al. (2024) studied this question.

synapsesocial.com/papers/68e57432b6db64358751442f https://doi.org/10.2967/jnumed.124.268020

View at Publisher

Ask AI

Bookmark

Share

Intrapatient Intermetastatic Heterogeneity Determined by Triple-Tracer PET Imaging in mCRPC Patients and Correlation to Survival: The 3TMPO Cohort Study

Ask about this paper

Abstract

Discussion

Cite This Study

Intrapatient Intermetastatic Heterogeneity Determined by Triple-Tracer PET Imaging in mCRPC Patients and Correlation to Survival: The 3TMPO Cohort Study

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading